Private Placement

BioLineRx secures crucial funds for its cancer drugs, but at a cost. We dissect the deal, the shareholder dilution, and what it reveals about biotech financing.

A NASDAQ-listed shipping firm scuttles its entire fleet to become a digital asset powerhouse. SVRN's all-in bet on NEAR Protocol is a bold reinvention.

NexPoint's new marina fund reveals a trend: institutional cash flowing into niche waterfront assets. But are these safe harbors or risky waters for investors?

AIxCrypto is pivoting from crypto to a robot-sharing platform, touting a disciplined strategy. But with a 'going concern' warning, can it succeed?

Avenzo Therapeutics' new CHRO hire is more than a personnel move; it's a critical piece of a master plan for a public debut and oncology market disruption.

Machine Investment Group defies a tough market, raising $470M to hunt for distressed and special situation real estate in the often-overlooked middle market.

Leading Edge Materials nets C$4M in a strategic financing, fast-tracking its Swedish rare earth and graphite projects vital for the EU's green transition.

Errington Metals isn't just drilling; it's making a calculated move to redefine the Sudbury Basin. High-grade silver and a major financing signal a serious VMS play.

Diodes Inc. secures a massive, interest-free war chest. While markets flinched at the news, the move reveals a calculated strategy for acquisitions and growth.

Quince Therapeutics bets its future on an inhaled lung disease drug, LAM-001, after acquiring Orphai and securing a $115M financing to fuel its new mission.

Copenhagen Infrastructure Partners' new fund isn't just a number; it's a blueprint for how to de-risk and power the next wave of global growth.

With fully funded facilities and a US Army pact, REalloys is building a non-Chinese magnet supply chain. But can its strategic wins outweigh a $37M loss?

With a novel drug platform and new funding, Akari Therapeutics aims to redefine cancer therapy. But can its groundbreaking science outpace a ticking financial clock?

The InsurTech firm posted a Q2 loss and falling revenue, but its forward-looking metrics tell a different story. A deep dive into a high-stakes bet on AI.

Facing a 'going concern' warning, Pulmatrix abandons its drug pipeline for a reverse merger, betting its survival on the high-risk field of longevity science.

LightInTheBox secures $5.49M for an AI overhaul, with its CEO personally investing $1.09M. Is this the catalyst needed to thrive in a crowded market?

After securing a $114M financing deal, Pyxis Oncology has extended its runway into 2027, putting all focus on upcoming MICVO data for head and neck cancer.

Opendoor secured $440M in zero-interest capital while buying back stock. Is this a financial masterstroke paving a path to profit or a complex bet on a risky future?

Multitude Capital's H1 report shows declining profits but a €70M funding coup. We unpack the strategic genius behind fueling a FinTech empire.

A private group aims to raise $25M to unlock Tanzania's vast mineral wealth. Is this a new model for development or a repeat of the old extraction playbook?